The two isoforms, such as neuropilin-1 (NRP1) and neuropilin-2 (NRP2), are often upregulated in various clinical disorders, including cancer, where they increase the oncogenic activities of malignant cells by promoting survival, inducing angiogenesis and lymphangiogenesis and contribute to therapy resistance. This evidence concerns the gene NRP1 and cancer.